Medistim ASA · OSL:MEDI

Medistim ASA — Q2 2013 Earnings Presentation

24 slides from Medistim ASA's earnings presentation, Aug 20, 2013

  1. Slide 1: Medistim ASA Second Quarter 2013

    Medistim ASA Second Quarter 2013 Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO August 20th, 2013

  2. Slide 2: Disclaimer

    2 20.08.2013 Medistim ASA Q2 2013 Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Medistim ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These s

  3. Slide 3: Table of contents

    3 20.08.2013 Medistim ASA Q2 2013 Table of contents 1. Highlights Second Quarter 2. Financial Statements 3. Business Segments Update 4. Implementing the Strategy

  4. Slide 4: 1. Highlights second quarter

    1. Highlights second quarter

  5. Slide 5: Highlights second quarter 2013

    5 20.08.2013 Medistim ASA Q2 2013 Highlights second quarter 2013 Q2 2013 QoQ • Sales revenues increases with 11.4 % o 51.1 % growth sales of own products Revenue 11.4% o 4.0 % increase in 3rd party products MNOK 49.0 (43.9) o Solid growth in VeriQ C revenue o Strong growth in system sales in Europe

  6. Slide 6: 2. Financial statements

    2. Financial statements

  7. Slide 7: Profit and loss Q2 2013

    7 20.08.2013 Medistim ASA Q2 2013 Profit and loss Q2 2013 Profit & loss Q2 2013 Q2 2012 Sales per Quarter (TNOK) All numb ers in NOK 1000 55 000 Sales 48 962 43 948 50 000 Cost of goods sold 11 428 11 311 45 000 Salary and sosial expenses 13 205 11 622 40 000 Other operating expenses 9 609 9 151 35

  8. Slide 8: Profit and loss H1 2013

    8 20.08.2013 Medistim ASA Q2 2013 Profit and loss H1 2013 Profit & loss 1st half 2013 1st half 2012 Sales per Quarter (TNOK) All numb ers in NOK 1000 55 000 Sales 94 468 89 002 50 000 Cost of goods sold 23 619 23 956 45 000 Salary and sosial expenses 28 349 26 154 Other operating expenses 18 681 17

  9. Slide 9: Balance sheet - Assets

    9 20.08.2013 Medistim ASA Q2 2013 Balance sheet - Assets Balance sheet 30.06.2013 31.12.2012 180 000 All numb ers in NOK 1000 160 000 Assets 140 000 120 000 Intangible assets 45 518 42 288 100 000 Fixed assets 13 561 10 944 80 000 Total intangible and fixed assets 59 079 53 232 60 000 Inventory 40 0

  10. Slide 10: Balance sheet - Equity and liability

    10 20.08.2013 Medistim ASA Q2 2013 Balance sheet - Equity and liability Balance sheet 30.06.2013 31.12.2012 180 000 All numb ers in NOK 1000 160 000 140 000 Share capital 4 585 4 585 120 000 Premium fund 41 852 41 852 100 000 Other equity 63 920 68 732 80 000 Total equity 110 357 115 170 60 000 40 0

  11. Slide 11: 3. Business segments update

    3. Business segments update

  12. Slide 12: Flow probes and VeriQ sales in units

    12 20.08.2013 Medistim ASA Q2 2013 Flow probes and VeriQ sales in units Flow probes in units VeriQ systems in units 1 600 35 1 500 30 1 400 25 1 300 20 1 200 15 1 100 10 1 000 5 0 900 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Asia Eur

  13. Slide 13: Imaging probes and VeriQ C sales in units

    13 20.08.2013 Medistim ASA Q2 2013 Imaging probes and VeriQ C sales in units Imaging probes in units VeriQ C systems in units 14 20 18 12 16 10 14 12 8 10 6 8 6 4 4 2 2 0 0 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Imaging probes US i

  14. Slide 14: Q2 revenue performance by region

    14 20.08.2013 Medistim ASA Q2 2013 Q2 revenue performance by region Mill NOK Q2 '13 Q2 '12 Q/Q H1'13 H1' 12 H/H 2012 Europe 31,1 25,3 23,0 % 57,8 51,9 11,4 % 107,0 USA 10,3 12,4 -16,6 % 23,1 23,7 -2,4 % 48,5 Asia & Jp 2,9 3,4 -14,7 % 6,5 8,2 -20,7 % 18,4 ROW 4,6 2,8 64,3 % 7,0 5,2 34,6 % 9,8 (MEA, C

  15. Slide 15: Q2 revenue performance by product

    15 20.08.2013 Medistim ASA Q2 2013 Q2 revenue performance by product Mill NOK Q2 '13 Q2 '12 Q/Q H1 '13 H1 '12 H/H 2012 Procedures (USA) 10,3 10,7 -3,7 % 20,9 21,5 -2,8 % 42,8 Flow probes 13,1 11,7 12,0 % 25,7 24,2 6,2 % 47,3 Flow systems (VeriQ) 4,0 5,1 -21,6 % 8,0 7,9 1,3 % 17,9 Imaging systems (Ve

  16. Slide 16: Trend shift in the US market

    16 20.08.2013 Medistim ASA Q2 2013 Trend shift in the US market Trend shift in procedure growth # of Procedures per Consecutive Quarter % Year over Year procedure growth 9 000 14 8 500 12 8 000 10 7 500 8 7 000 6 6 500 4 6 000 2 5 500 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2009 2010 2011

  17. Slide 17: 4. Implementing the strategy

    4. Implementing the strategy

  18. Slide 18: Medistim owns a high share of an underdeveloped market

    18 20.08.2013 Medistim ASA Q2 2013 Medistim owns a high share of an underdeveloped market CABG MARKET PENETRATION SHARE OF PENETRATED MARKET 20 % 7% 5% 2% No Quality Assurance: 19% > 73 % 74% Medistim Transonic Other No Quality Assurance

  19. Slide 19: Standard of Care

    19 20.08.2013 Medistim ASA Q2 2013 Lobbying, PR, STRATEGIC IMPERATIVES Digital In CABG Health marketing economy ”Standard model of Care” EU & NICE, developed INFLUENCE PAYORS Ground- AND breaking new PATIENTS studies in New, LOBBYING planning PROVIDE Disruptive RETURN NEW MEDIA Marketing ON INVESTME

  20. Slide 20: Strategic directions and priorities

    20 20.08.2013 Medistim ASA Q2 2013 EXPANDING OUR STRATEGY Strategic directions and priorities Emerging, 1. Within mature markets for CABG; high-growth convert our large installed base of flowmeters to markets our latest innovation the VeriQ C™ (BRICs) Under- 2. Through marketing and product developm

  21. Slide 21: Significant Endorsement Achieved from NICE

    21 22.02.2012 Medistim ASA Q4 2011 Significant Endorsement Achieved from NICE  On November 16th, NICE issued guidance supporting the routine use of Medistim’s VeriQ™ flowmeter system within UK’s National Health Service NICE guidance supports use  Both the clinical and economical benefit of VeriQ o

  22. Slide 22: Break-through in the UK

    22 20.08.2013 Medistim ASA Q2 2013 Break-through in the UK • First sales order from the UK since establishing a subsidiary and direct sales force in 2012 • This is a direct result from the NICE endorsement from late 2011 “…evidence suggests that routine use has • Medistim’s goal is to establish qual

  23. Slide 23: A great reference center

    23 20.08.2013 Medistim ASA Q2 2013 A great reference center “At the Queen Elizabeth hospital, we recognize the importance of quality • Queen Elizabeth Hospital Birmingham is part of assurance in cardiac surgery. the University Hospitals Birmingham NHS The Medistim TTFM / VeriQ C Foundation Trust, wh

  24. Slide 24: Seeing is believing

    24 20.08.2013 Medistim ASA Q2 2013 Seeing is believing

Medistim — Q2 2013 Earnings Presentation on 6ix